CIK 0000882796 · Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 621413174
- Phone
- 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-19 | Thackray Helen M. Chief R&D Officer | Shares withheld for taxes | −5,580 | $6.05 | $34K | 249,664 |
| 2023-12-19 | Stonehouse Jon P President & CEO | Shares withheld for taxes | −14,089 | $6.05 | $85K | 1,114,770 |
| 2023-12-19 | Gayer Charles K Chief Commercial Officer | Shares withheld for taxes | −2,482 | $6.05 | $15K | 274,533 |
| 2023-12-19 | Doyle Anthony Chief Financial Officer | Shares withheld for taxes | −2,482 | $6.05 | $15K | 227,444 |
| 2023-12-19 | Barnes Alane P Chief Legal Officer | Shares withheld for taxes | −2,482 | $6.05 | $15K | 293,539 |
| 2023-12-14 | Thackray Helen M. Chief R&D Officer | Grant or award | +51,000 | 258,275 | ||
| 2023-12-14 | Thackray Helen M. Chief R&D Officer | Shares withheld for taxes | −3,031 | $6.43 | $19K | 255,244 |
| 2023-12-14 | Thackray Helen M. Chief R&D Officer | Grant or award · Emp. Stock Option (Right to Buy) | +238,000 | 238,000 | ||
| 2023-12-14 | Stonehouse Jon P President & CEO | Grant or award | +127,500 | 1,142,451 | ||
| 2023-12-14 | Stonehouse Jon P President & CEO | Shares withheld for taxes | −13,592 | $6.43 | $87K | 1,128,859 |
| 2023-12-14 | Stonehouse Jon P President & CEO | Grant or award · Emp. Stock Option (Right to Buy) | +595,000 | 595,000 | ||
| 2023-12-14 | Gayer Charles K Chief Commercial Officer | Grant or award | +34,000 | 282,855 | ||
| 2023-12-14 | Gayer Charles K Chief Commercial Officer | Shares withheld for taxes | −5,840 | $6.43 | $38K | 277,015 |
| 2023-12-14 | Gayer Charles K Chief Commercial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +158,500 | 158,500 | ||
| 2023-12-14 | Doyle Anthony Chief Financial Officer | Grant or award | +34,000 | 235,401 | ||
| 2023-12-14 | Doyle Anthony Chief Financial Officer | Shares withheld for taxes | −5,475 | $6.43 | $35K | 229,926 |
| 2023-12-14 | Doyle Anthony Chief Financial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +158,500 | 158,500 | ||
| 2023-12-14 | Barnes Alane P Chief Legal Officer | Grant or award | +64,000 | 300,036 | ||
| 2023-12-14 | Barnes Alane P Chief Legal Officer | Shares withheld for taxes | −4,015 | $6.43 | $26K | 296,021 |
| 2023-12-14 | Barnes Alane P Chief Legal Officer | Grant or award · Emp. Stock Option (Right to Buy) | +158,500 | 158,500 |
Page 10 of 18 · 357 trades